Bortezomib in Treating Patients With Lymphoproliferative Disorders

Inclusion Criteria: Histologically or cytologically confirmed lymphoproliferative disorder of 1 of the following subtypes: * Relapsed or refractory grade I, II, or III follicular center cell lymphoma Relapsed or refractory mantle cell lymphoma Measurable disease for non-Hodgkin's lymphoma (NHL) only At least 1 unidimensionally measurable lesion At least 2 cm by conventional techniques OR at least 1 cm by spiral CT scan Lymph nodes no greater than 1 cm in short axis considered normal Absolute lymphocytosis greater than 5,000/mm^3 with B-cell phenotype (CD19, 20,or 23 positive) with more than 30% bone marrow lymphocytes for CLL or other leukemic forms of NHL No known brain metastases Performance status - Karnofsky 70-100% At least 3 months See Disease Characteristics Absolute neutrophil count greater than 1,500/mm^3 (500/mm^3 if lymphomatous involvement of bone marrow) Platelet count greater than 50,000/mm^3 Bilirubin less than 1.5 times upper limit of normal (ULN) AST and ALT no greater than 2.5 times ULN (4 times ULN in case of liver metastases) Creatinine less than 1.5 times ULN No symptomatic congestive heart failure No New York Heart Association class III or IV heart disease No unstable angina pectoris No cardiac arrhythmia No myocardial infarction within the past 6 months No cerebrovascular accident or transient ischemic attack within the past 6 months No history of orthostatic hypotension No evidence of acute ischemia or significant conduction abnormality (left anterior hemiblock in the presence of right bundle branch block or second or third degree atrioventricular blocks) on electrocardiogram No uncontrolled hypertension requiring antihypertensive medication Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Febrile episodes up to 38.5°C allowed if no evidence of active infection No other uncontrolled concurrent illness No known or active HIV infection No ongoing or active infection No psychiatric illness or social situation that would preclude study entry At least 3 months since prior monoclonal antibody therapy (e.g., rituximab) No more than 3 prior regimens of conventional cytotoxic chemotherapy At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered At least 1 week since prior steroid therapy At least 4 weeks since prior radiotherapy and recovered At least 4 weeks since prior major surgery No other concurrent investigational agents